Novo Nordisk - Business Overview
Business overview of Novo Nordisk and its competitive position.
novo-nordiskpharmaceuticalglp-1weight-loss-drugsdiabetesdanish-companybusinessoverview
Novo Nordisk - Business Overview
Novo Nordisk is a Danish pharmaceutical company that has become the global pioneer in GLP-1 (glucagon-like peptide-1) weight loss drugs. Founded in 1923, the company has transformed from a diabetes-focused insulin manufacturer into the leader of a potentially $100-350 billion obesity treatment market. Despite a 45% share price drawdown in 2024, Fundsmith maintains its position, viewing it as one of the most compelling quality businesses in their portfolio.
Learn more at Novo Nordisk